5-Bromo-4-fluoro-1-methyl-1H-indazole

Physicochemically, it is a stable solid with a predicted density of 1.70±0.1g/cm³ and boiling point of 293.4±20.0°C. It exhibits favorable solubility in polar organic solvents, fitting mainstream pharmaceutical synthesis processes. Its unique structural design, combining bromo, fluoro and methyl groups on the indazole ring, boosts reaction compatibility and lays a solid foundation for subsequent structural modification in drug synthesis.

It complies with strict pharmaceutical-grade QC standards, with core indicators including purity ≥99% and single impurity ≤0.1% (tested by HPLC). Heavy metals and impurities are strictly controlled to avoid affecting synthesis efficiency and product quality. Purified via mature processes, it ensures batch-to-batch consistency and meets large-scale pharmaceutical production requirements, reducing customer risks and costs.

Easy to store and transport, it is packaged in pharmaceutical-grade containers (1kg/10kg options) with a long shelf life. It should be stored in a cool, dry, well-ventilated environment, away from heat, strong light, oxidants and acids/alkalis, to prevent decomposition and ensure stability during storage and transportation.

Widely applied in pharmaceutical synthesis, it is a key intermediate for heterocyclic drugs and high-demand oral small-molecule GLP-1 agonists like Orforglipron (for diabetes/obesity treatment). Its stable indazole scaffold and functional groups match Orforglipron’s molecular construction needs, simplifying synthesis and improving yield. Amid booming global GLP-1 demand, it is a high-potential choice for enterprises pursuing efficient, high-quality new drug R&D and bulk production.